• PML Risk
    Stratification
  • Anti-JCV
    Antibody Test
PML RISK STRATIFICATION

NOW IS THE TIME:
DETECT ANTI-JCV ANTIBODIES AND ASSESS PML RISK

Testing for anti-JC virus (JCV) antibodies is recommended in patients considering or receiving TYSABRI1

THE RISKS AND BENEFITS OF CONTINUING TYSABRI SHOULD BE CAREFULLY CONSIDERED IN PATIENTS WHO ARE ANTI-JCV POSITIVE AND HAVE ONE OR MORE ADDITIONAL RISK FACTORS.1

References

  1. TYSABRI Prescribing Information. Cambridge, MA: Biogen Idec
  2. Sunyaev SR, Lugovskoy A, Simon K, Gorelik L. Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML). PLoS Genet. 2009;5(2):e1000368. Epub 2009 Feb 6.
  3. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68(3):295-303.
Indication
TYSABRI® (natalizumab) is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis. TYSABRI increases the risk of PML. When initiating and continuing treatment with TYSABRI, physicians should consider whether the expected benefit of TYSABRI is sufficient to offset this risk. See important information regarding the risk of PML with TYSABRI.

Please see full Prescribing Information, including Boxed Warning for Important Safety Information.

You are leaving this site. This link will take you to a website that is outside the control of Biogen Idec. We provide links as a public service and for informational purposes only. We do not make or imply any endorsement of external web sites.

Click Cancel to return or OK to continue.

  

You have clicked on a link that will take you out of this website.

Click Cancel to return or OK to continue.

  

Blank Overlay Used To Show Alert Messages Automatically

Submission Is In Progress
One Moment Please.

Accepting outside referrals indicates an infusion site is willing to accept patients outside of their current practice. If they do not accept outside referrals then they only accept patients who are part of their current practice.

THANK YOU FOR REGISTERING!

We look forward to sharing exclusive information and updates about TYSABRI.

THANK YOU

Your profile is updated.